Brian Brueck
Umoja Biopharma Announces FDA Clearance of IND for UB-VV400, First Known CD22-Directed In Vivo CAR T for Relapsed/Refractory B Cell Malignancies
Umoja Biopharma received FDA clearance for its IND for UB-VV400, the company's lead in vivo CD22-directed CAR T therapy targeting relapsed/refractory B cell malignancies, advancing its clinical pipeline toward first patient dosing.
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
Umoja Biopharma appointed Dr. Marcela Maus and Dr. Athena Countouriotis to its board of directors, expanding leadership with experienced biotech and cell therapy experts.
